6-K
ASTRAZENECA PLC (AZN)
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For the month of June 2025
Commission File Number: 001-11960
AstraZeneca PLC
1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge CB2 0AA
United Kingdom
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F X Form 40-F __
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate by check mark whether the registrant by furnishing the information contained in this Form is
also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes __ No X
If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________
AstraZeneca PLC
INDEX TO EXHIBITS
1.
Block listing Interim Review
2 June 2025
BLOCK LISTING SIX MONTHLY RETURN
Information provided on this form must be typed or printed electronically and provided to an ris.
(Note: Italicised terms have the same meaning as given in the Listing Rules.)
Date: 2 June 2025
| Name<br>of applicant: | ASTRAZENECA<br>PLC | |||
|---|---|---|---|---|
| Name of<br>scheme: | ASTRAZENECA SHARE OPTION PLAN; ASTRAZENECA<br>SAVINGS-RELATED SHARE<br>OPTION PLAN; ASTRAZENECA ALL-EMPLOYEE SHARE PLAN; ASTRAZENECA PLC<br>2012 SAVINGS-RELATED SHARE OPTION SCHEME | |||
| Period<br>of return: | From: | 1<br>DECEMBER 2024 | To: | 31 MAY<br>2025 |
| Balance<br>of unallotted securities under scheme(s) from previous<br>return: | 4,029,156 | |||
| Plus: The<br>amount by which the block scheme(s) has been increased since the<br>date of the last return (if any increase has been applied<br>for): | 0 | |||
| Less: Number<br>of securities issued/allotted under scheme(s) during<br>period (see UKLR 20.6.7G): | 340,773 | |||
| Equals: Balance<br>under scheme(s) not yet issued/allotted at end of<br>period: | 3,688,383 | |||
| Name of<br>contact: | Hannah<br>Tattersall | |||
| --- | --- | |||
| Telephone<br>number of contact: | +44<br>(0)20 3749 5000 |
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on social media @AstraZeneca
Contacts
For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.
Matthew Bowden
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| AstraZeneca<br>PLC |
|---|
Date: 02 June 2025
| By: /s/<br>Adrian Kemp |
|---|
| Name:<br>Adrian Kemp |
| Title:<br>Company Secretary |